BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 9748560)

  • 1. Clinical applications of anticancer drugs targeted to topoisomerase II.
    Hande KR
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):173-84. PubMed ID: 9748560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity of the topoisomerase II inhibitors.
    Seiter K
    Expert Opin Drug Saf; 2005 Mar; 4(2):219-34. PubMed ID: 15794715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.
    Hartmann JT; Lipp HP
    Drug Saf; 2006; 29(3):209-30. PubMed ID: 16524321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential regulation of NF-kappaB activation and function by topoisomerase II inhibitors.
    Campbell KJ; O'Shea JM; Perkins ND
    BMC Cancer; 2006 Apr; 6():101. PubMed ID: 16630341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide: four decades of development of a topoisomerase II inhibitor.
    Hande KR
    Eur J Cancer; 1998 Sep; 34(10):1514-21. PubMed ID: 9893622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topoisomerase inhibitors. A review of their therapeutic potential in cancer.
    Sinha BK
    Drugs; 1995 Jan; 49(1):11-9. PubMed ID: 7705211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitoxantrone, More than Just Another Topoisomerase II Poison.
    Evison BJ; Sleebs BE; Watson KG; Phillips DR; Cutts SM
    Med Res Rev; 2016 Mar; 36(2):248-99. PubMed ID: 26286294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA topoisomerase II inhibitors.
    IARC Monogr Eval Carcinog Risks Hum; 2000; 76():175-344. PubMed ID: 11000976
    [No Abstract]   [Full Text] [Related]  

  • 9. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.
    Pommier Y; Leo E; Zhang H; Marchand C
    Chem Biol; 2010 May; 17(5):421-33. PubMed ID: 20534341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical development of topoisomerase-interactive drugs.
    Muggia FM; Burris HA
    Adv Pharmacol; 1994; 29B():1-31. PubMed ID: 8996599
    [No Abstract]   [Full Text] [Related]  

  • 11. Discovery of podophyllotoxins.
    Imbert TF
    Biochimie; 1998 Mar; 80(3):207-22. PubMed ID: 9615861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical modulation of cytotoxic drugs by cytokines: molecular mechanisms in experimental oncology.
    Kreuser ED; Wadler S; Thiel E
    Recent Results Cancer Res; 1995; 139():371-82. PubMed ID: 7597304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II.
    Lee KC; Bramley RL; Cowell IG; Jackson GH; Austin CA
    Biochem Pharmacol; 2016 Mar; 103():29-39. PubMed ID: 26794000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between expression of topoisomerase II isoforms and chemosensitivity in choroidal melanoma.
    Satherley K; de Souza L; Neale MH; Alexander RA; Myatt N; Foss AJ; Hungerford JL; Hickson ID; Cree IA
    J Pathol; 2000 Oct; 192(2):174-81. PubMed ID: 11004693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
    Gieseler F; Glasmacher A; Kämpfe D; Wandt H; Nuessler V; Valsamas S; Kunze J; Wilms K
    Leukemia; 1996 Jul; 10 Suppl 3():S46-S49. PubMed ID: 8656700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
    Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
    Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catalytic inhibitors of DNA topoisomerase II.
    Andoh T; Ishida R
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):155-71. PubMed ID: 9748552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design, synthesis and biological testing of piperazine-linked bis-epipodophyllotoxin etoposide analogs.
    Yadav AA; Chee GL; Wu X; Patel D; Yalowich JC; Hasinoff BB
    Bioorg Med Chem; 2015 Jul; 23(13):3542-51. PubMed ID: 25922181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA topoisomerase II poisons and inhibitors.
    Capranico G; Giaccone G; Zunino F; Garattini S; D'Incalci M
    Cancer Chemother Biol Response Modif; 1997; 17():114-31. PubMed ID: 9551211
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.